Vivani Medical, Inc. · NASDAQ:VANI
Vivani Medical — Second Sight Medical Products — Investor Presentation (September 2018)
14 slides from Vivani Medical's investor presentation, Sep 4, 2018
Slide 1: Enriching the Lives of the Blind
&: Second Sight NASDAQ; EYES Enriching the Lives of the Blind September 2018
Slide 2: Forward Looking Statements
Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the "safe harbor" Create
Slide 3: Two Breakthrough Technologies
NASDAQ: EYES Two Breakthrough Technologies Argus® II ' Orion™ retinal prosthesis | visual cortical prosthesis system * First and only FDA approved retinal | * Leveraging Argus II technology prosthesis, Bypasses the retina and optic nerve to * — 20+years and ~$200 million invested to directly stimula
Slide 4: Argus II: Effective Treatment for Blindness
Slide 5: Strategic Priorities
rategic Priority Research ©» Second Sight + 6 subject feasibility study at UCLA and Baylor ongoing + FDA Breakthrough Device designation for expedited path + Projects underway to iterate implant design and externals in preparation for pivotal trial Commercial focus on capital efficiency & leverage +
Slide 6: Leveraging Argus II technology, our breakthrough Orion platform bypasses the damaged eye
Leveraging Argus II technology, our breakthrough Orion platform bypasses the damaged eye and/or optic nerve to directly stimulate the brain * Orion has the potential to treat many forms of blindness including glaucoma, diabetic retinopathy, optic nerve disease and trauma * Received FDA Breakthrough
Slide 7: Encouraging Early Orion Feasibility Study Results
Encouraging Early Orion Feasibility Study Results * Conducting a six subject feasibility study at UCLA Medical Center and the Baylor College of Medicine * Five subjects implanted and activated in 1H 2018 * Allreport seeing spots of light on virtually all electrodes * Observations from our early test
Slide 8: COE model and artificial vision rehabilitation
COE model and artificial vision rehabilitation + Centers of Excellence model to build regional Argus centers + Best practices development and pioneered post-surgical rehabilitation to improve patient satisfaction and outcomes f) Effective patient outreach & screening with U.S. patient database * Eff
Slide 9: Argus Strategy: Capital Efficiency and Strategic Value
Argus Strategy: Capital | Value i Develop Argus commercial competencies that are strategic for Orion © Patient outreach, patient qualification & U.S. patient database * Artificial vision rehabilitation expertise
Slide 10: Research Projects to Enhance User Experience
NASDAQ: EYES x Research Projects to Enhance User Experience Eyetracking Depth based decluttering + Move the implant field of + Allow users tofiter out view in conjunction with objects further than a the movement of the defined distance users eyes Thermalimaging Object recognition + Infrared imaging
Slide 11: Drivers of Shareholder Value
Drivers of Shareholder Value thr Orion wy Complete Orion feasibility trial and release interim Initiate Orion BEZE data from first 6 patients Pivotal Trial Agreement on pivotal and post-market trial designs AgteaienbefEDR via the FDA's Breakthrough Device Program for Orion Clinical & \ ) Initiation
Slide 12: Select Financial Data
Select Financial Data Q22018 FY 2017 FY2016 75 42 Implants 7, ome) wane Revenue $1,907 $7,964 $3,985 Gross Profit (Loss) $1,071 $2,847 $(6,091) Net Loss $(7,961) $(28,516) $(33,179) Non-GAAP Adjusted Net Loss? $(7,120) $(27,576) $(24,812) (USD $ in tho ids) June 30, 2018 December 31, 2017 Cash and c
Slide 13: Second Sight Investment Highlights
Second Sight Investment Highlights Argus II business focused on capital efficiency and strategic benefit * RO! and cost structure improvements important when evaluating markets or expansion * Commercial competencies and R&D efforts such as Argus 2s next-gen externals that benefit Orion are prioritiz
Slide 14: Contacts
Contacts Second Sight Medical Products, Inc. 12744 San Fernando Road Suite 400 Sylmar, CA 91342 Main: 818-833-5000 www.secondsight.com Will McGuire President & CEO Direct: 818-833-5040 wmeguire@secondsight.com Retail Investor Relations Institutional Investor Relations Greg Falesnik Lisa Wilson Manag
Second Sight Medical Products — Investor Presentation (September 2018) on 6ix